Patents by Inventor Michel Nussenzweig

Michel Nussenzweig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150439
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
    Type: Application
    Filed: April 24, 2023
    Publication date: May 9, 2024
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Davide F. Robbiani
  • Patent number: 11919945
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: March 5, 2024
    Assignee: The Rockefeller University
    Inventor: Michel Nussenzweig
  • Patent number: 11897940
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: February 13, 2024
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Publication number: 20240002480
    Abstract: This disclosure provides novel broadly neutralizing anti-tick-borne encephalitis virus (TBEV) antibodies. The disclosed anti-TBEV antibodies represent a novel therapeutic strategy for preventing or treating diseases or infections caused by various tick-borne flaviviruses, including TBEV.
    Type: Application
    Filed: November 23, 2021
    Publication date: January 4, 2024
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Davide F. Robbiani
  • Publication number: 20230365661
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: February 22, 2023
    Publication date: November 16, 2023
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Publication number: 20230279082
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 7, 2023
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Publication number: 20230192823
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Application
    Filed: October 13, 2022
    Publication date: June 22, 2023
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Publication number: 20230181636
    Abstract: This disclosure provides modified B cells which produce heterologous antibodies and co-express cargo proteins. The modified B cells may be stimulated by binding of a cognate antigen to the heterologous antibodies. The B cells may be reduced or eliminated by contacting the heterologous antibody with an anti-idiotypic antibody. Methods of making, and using the modified B cells for prophylaxis and therapy for a variety of conditions are provided. The B cells are modified at an IgH locus, an IgK locus, and combinations thereof. Modified B cells maintain allelic exclusion.
    Type: Application
    Filed: March 18, 2021
    Publication date: June 15, 2023
    Inventors: Harald HARTWEGER, Mila JANKOVIC, Michel NUSSENZWEIG
  • Patent number: 11649276
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: May 16, 2023
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11634478
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: April 25, 2023
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Patent number: 11634477
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: April 25, 2023
    Assignee: The Rockefeller University
    Inventors: Michel Nussenzweig, Davide F. Robbiani
  • Publication number: 20220348642
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Application
    Filed: March 30, 2022
    Publication date: November 3, 2022
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Publication number: 20220315645
    Abstract: Provided are broadly neutralizing antibodies (bNAbs) and antigen binding fragments thereof that bind with specificity to epitopes expressed by Hepatitis B vims (HBV). The bNAbs target non-overlapping epitopes on the HBV S antigen (HBsAg). Pharmaceutical compositions that contain the bNAbs, or modified bNAbs, are provided. Combinations of the bNAbs are included, and are useful for prophylaxis and therapy of HBV infection, and for inhibiting development of HBV escape mutations in infected individuals. Expression vectors encoding the bNAbs and antigenic fragments of them are included, as are methods of making the bNAbs and antigenic fragments of them. HBV peptides for use as vaccines are provided, and include at least two non-overlapping epitopes from the HBsAg. Diagnostic reagents comprising the bNAbs or antigenic fragments thereof are provided, as are methods of detecting HBV and diagnosing HBV infection.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 6, 2022
    Inventors: Qiao WANG, Michel NUSSENZWEIG
  • Publication number: 20220306729
    Abstract: Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.
    Type: Application
    Filed: May 19, 2022
    Publication date: September 29, 2022
    Inventors: Davide ROBBIANI, Michel NUSSENZWEIG
  • Publication number: 20220227844
    Abstract: This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
    Type: Application
    Filed: January 13, 2022
    Publication date: July 21, 2022
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Zijun Wang
  • Patent number: 11370830
    Abstract: Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 28, 2022
    Assignee: The Rockefeller University
    Inventors: Davide Robbiani, Michel Nussenzweig
  • Publication number: 20220195015
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.
    Type: Application
    Filed: November 4, 2021
    Publication date: June 23, 2022
    Applicant: The Rockefeller University
    Inventor: Michel Nussenzweig
  • Publication number: 20220169707
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Application
    Filed: October 13, 2021
    Publication date: June 2, 2022
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Ron Diskin, Anthony P. West, Michel Nussenzweig, Pamela J. Bjorkman
  • Patent number: 11325966
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 10, 2022
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Publication number: 20220119504
    Abstract: The present disclosure provides optimized broadly-neutralizing anti-HIV antibodies, having modified light chain variable regions and/or heavy chain variable regions leading to improved biophysical characteristics. The present disclosure also provides methods for producing these anti-HIV antibodies and methods of use thereof.
    Type: Application
    Filed: September 12, 2019
    Publication date: April 21, 2022
    Inventors: Michel Nussenzweig, Randal R. Ketchem, Christine C. Siska, Alison J. Gillespie, Rutilio H. Clark, Bruce A. Kerwin